Phone: 8128 4694
Doctor of Philosophy (PhD), Adelaide Medical School, The University of Adelaide (2018)
Honours Degree, School of Medical Sciences, The University of Adelaide (1999)
Bachelor of Applied Science, University of South Australia (1998)
Dr Krzysztof M. Mrozik completed his PhD studies in 2018 at the The University of Adelaide, Australia. His PhD research focused on identifying novel therapeutic targets in the haematological cancer multiple myeloma (MM). These studies identified that targeting of a cell adhesion molecule, N-cadherin, as a monotherapy, or in combination with the anti-MM agent bortezomib, could potentially delay or prevent MM disease relapse. During his PhD candidature, Dr Mrozik received numerous honours including the Lawrence Catley Memorial Award for Best Abstract at the 2016 National Myeloma Workshop, and he was a 2018 Ross Wishart Memorial Award finalist at the ASMR SA Scientific Meeting. Dr Mrozik was also awarded a Dean’s Commendation for Doctoral Thesis Excellence.
In July 2018, Dr Mrozik commenced a postdoctoral position in the Myeloma Research Laboratory based at SAHMRI with Prof. Andrew C.W. Zannettino and Dr Kate Vandyke. To date, Dr Mrozik has co-authored 22 publications, including 8 as first author.
Debilitating drug treatment-related side effects and disease relapse currently represent major challenges in the therapeutic management of individuals with MM. Dr Mrozik is developing novel strategies to increase efficacy and decrease side-effects of commonly used anti-MM agents, by selectively increasing drug delivery to sites of tumour and reducing exposure to healthy tissues. He is also investigating strategies to eliminate dormant, therapy-resistant cancer cells in order to delay or prevent MM disease relapse. As a passionate and highly motivated medical researcher, Dr Mrozik’s goal is to palpably improve the quality-of-life and survivorship of individuals with MM and other cancers.
Publications (last 10 years)
1.Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K: N-cadherin in cancer metastasis, its emerging roles in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer 2018, 18(1):939 (IF 3.2; 3 citations).
2.Vandyke K, Zeissig MN, Hewett DR, Martin SK, Mrozik KM, Cheong CM, Diamond P, To LB, Gronthos S, Peet DJ et al: HIF-2alpha Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. Cancer Res 2017, 77(20):5452-5463 (IF 9.3; 5 citations).
3.Mrozik KM, Gronthos S, Shi S, Bartold PM: A Method to Isolate, Purify, and Characterize Human Periodontal Ligament Stem Cells. Methods Mol Biol 2017, 1537:413-427 (IF 1.3, 5 citations).
4.Mrozik KM, Cheong CM, Hewett D, Chow AW, Blaschuk OW, Zannettino AC, Vandyke K: Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. Br J Haematol 2015, 171(3):387-399 (IF 4.7; 11 citations).
5.Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC: PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol 2015, 8:106 (IF 5.9; 9 citations).
6.Hynes K, Menicanin D, Mrozik K, Gronthos S, Bartold PM. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells and Development (2014), 23(10):1084-96 (IF 4.2; 65 citations).
7.Menicanin D, Mrozik KM, Wada N, Marino V, Shi S, Bartold PM, Gronthos S. Periodontal-ligament-derived stem cells exhibit the capacity for long-term survival, self-renewal, and regeneration of multiple tissue types in vivo. Stem Cells and Development (2014), 23(9):1001-11 (IF 4.2; 38 citations).
8.Han J, Menicanin D, Marino V, Ge S, Mrozik K, Gronthos S, Bartold PM. Assessment of the regenerative potential of allogeneic periodontal ligament stem cells in a rodent periodontal defect model. Journal of Periodontal Research (2014), 49(3):333-45 (IF 2.2; 28 citations).
9.Mrozik KM, Wada N, Marino V, Richter W, Shi S, Gronthos S, Bartold PM. Regeneration of periodontal tissues using allogeneic periodontal ligament stem cells in an ovine model. Regenerative Medicine (2013), 8(6):711-723 (IF 3.5; 18 citations).
10.Hynes K, Menicanin D, Han J, Marino V, Mrozik K, Gronthos S, Bartold PM. Mesenchymal stem cells from iPS cells facilitate periodontal regeneration. Journal of Dental Research (2013), 92(9):833-39 (IF 4.1; 54 citations).
11.Ge S, Mrozik KM, Menicanin D, Gronthos S, Bartold PM: Isolation and characterization of mesenchymal stem cell-like cells from healthy and inflamed gingival tissue: potential use for clinical therapy. Regen Med 2012, 7(6):819-832 (IF 2.9; 30 citations).
12.Mrozik KM, Xiong J, Gronthos S, Bartold PM. Proteomic characterization of mesenchymal stem cell-like populations derived from various tissue types. Stem Cells and Cancer Stem Cells; Therapeutic Applications in Disease and Injury (2012), 3(8) Springer Science.
13.Xiong J, Mrozik KM, Gronthos S, Bartold PM. Epithelial Cell Rests of Malassez contain unique stem cell populations capable of undergoing epithelial-mesenchymal transition. Stem Cells and Development (2012), 21(11):2012-25 (IF 4.2; 25 citations).
14.Mrozik KM, Gronthos S, Menicanin D, Marino V, Bartold PM. Effect of coating Straumann® Bone Ceramic with Emdogain on mesenchymal stromal cell hard tissue formation. Clinical Oral Investigations (2012), 16(3):867-78 (IF 2.3; 20 citations).
15.Mrozik KM, Zilm PS, Bagley CJ, Hack S, Hoffmann P, Gronthos S, Bartold PM. Proteomic Characterization of Mesenchymal Stem Cell-Like Populations Derived from Ovine Periodontal Ligament, Dental Pulp, and Bone Marrow: Analysis of Differentially Expressed Proteins. Stem Cells and Development (2010), 19(10):1485-99 (IF 4.2; 45 citations).
16.Mrozik K, Gronthos S, Shi S, Bartold PM. A Method to Isolate, Purify, and Characterize Human Periodontal Ligament Stem Cells. Oral Biology; Methods in Molecular Biology (2010), 666:269-84 (IF 1.3; 31 citations).
17.Gronthos S, McCarty R, Mrozik K, Fitter S, Paton S, Menicanin D, Itescu S, Bartold PM, Xian C, Zannettino AC: Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells Dev 2009, 18(9):1253-1262 (IF 3.6; 52 citations).